Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcγRIII (CD16) using real time kinetic analysis and flow cytometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 63, Issue , 2012, Pages 23-28

  Harrison, Alice ^a   Liu, Zhe ^a   Makweche, Schona ^a   Maskell, Kevin ^a   Qi, Hong ^a   Hale, Geoff ^a  

^a Millipore BioPharma Services   (United Kingdom)

Author keywords

CD16; Fc RIII; Flow cytometry; Surface plasmon resonance; Therapeutic antibody

Indexed keywords

ALEMTUZUMAB; CD16 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD16; OTELIXIZUMAB; UNCLASSIFIED DRUG;

ACCURACY; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOASSAY; KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN STRUCTURE; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; CHO CELLS; CRICETINAE; CRICETULUS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GLYCOSYLATION; GLYCOSYLTRANSFERASES; GPI-LINKED PROTEINS; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, IGG; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; TRANSFECTION;

EID: 84862797535     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.01.029     Document Type: Article

References (11)

1. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1988, 332:323-327.
2. Phillips J., Drumm A., Harrison P., Bird P., Bhamra K., Berrie E., Hale G. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials. Cytotherapy 2001, 3:233-242.
3. Armour K.L., Smith C.S., Clark M.R. Expression of human FcγRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding. J. Immunol. Methods 2010, 354:20-33.
4. Lifely R.M., Hale C., Boyce S., Keen M.J., Phillips J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995, 5:813-822.
5. Hatjiharissi E., Xu L., Santos D.D., Hunter Z.R., Ciccarelli B.T., Verselis S., Modica M., Cao Y., Manning R.J., Leleu X., Dimmock E.A., Kortsaris A., Mitsiades C., Anderson K.C., Fox E.A., Treon S.P. Increased natural killer cell expression of CD16 augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158V/V and V/F polymorphism. Blood 2007, 110:2561-2564.
6. Hu P., Turner M.J., Shields J., Gale M.S., Hutto E., Roberts B.L., Siders W.M., Kaplan J.M. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009, 128:260-270.
7. Umana P., Jean-Mairet J., Moudry R., Amstutz H., Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody dependent cellular cytotoxic activity. Nat. Biotechnol. 1999, 17:1276-2180.
8. Dyer M.J.S., Moser S., Brünker P., Bird P., Almond N., Puentener U., Wheat L.M.W., Bolam E., Berrie E., Grau R., Buckby E., Kennedy B., Stebbings R., Hale G., Umana P. Enhanced potency of glycoengineered anti-cd52 monoclonal antibodies. Blood (ASH Annual Meeting Abstracts) 2005, 106. Abstract 2958.
9. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De Block C., Seigneurin J-M., De Pauw P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J-F., Pipeleers D., Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type I diabetes. N. Engl. J. Med. 2005, 352:2598-2608.
10. Bracher M., Gould H.J., Sutton B.J., Dombrowicz D., Karagiannis S.N. Three-colour cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. J. Immunol. Methods 2007, 323:160-171.
11. Gottschalk P.G., Dunn J.R. Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data. J. Biopharm. Sci. 2005, 15:437-463.